Sigma-Aldrich (Nasdaq: SIAL)
today announced the global release of MISSION(R) esiRNA, a pool of gene-specific
siRNA that provides a novel and powerful approach to RNAi screening in mammalian
cells. Unlike traditional synthetic RNAi, esiRNA (www.sigma.com/esirna) incorporates
a pool of hundreds of siRNAs against a single gene target. This new tool is
designed to eliminate the trial and error approach of identifying a single siRNA
for gene knockdown and ensures minimal off-target effects.
"MISSION esiRNA provides a powerful way to elucidate gene function in
cell culture assays," said Dr. Supriya Shivakumar, global marketing manager
for Functional Genomics at Sigma-Aldrich. "The pooled format, unlike anything
else on the market, should enable researchers to knock down genes rapidly and
cost-effectively. This is an exciting addition to our current MISSION lineup
and provides an effective technology that will facilitate RNAi research for
a broad base of scientists."
The technique offers a number of benefits over the traditional approach to
single-siRNA gene knockdown. By targeting each gene target with a "super-pool"
of siRNA, the trial and error approach of identifying a useful single siRNA
is eliminated. In addition, the approach should ensure minimal risk of off-target
effects and enables the use of one assay per gene. Development of the esiRNA
approach was supported by the German BMBF program "GO-Bio" and developed
by the Max Planck Institute for Cell Biology and Genetics (MPI-CBG) in Dresden,
Frank Buchholz, a research group leader at the MPI-CBG, has pioneered the use
of the esiRNA technology in RNAi screens. "We are delighted to be partnering
with Sigma-Aldrich to make esiRNA technology available to the research community,"
he said. "esiRNAs were invented in Mike Bishop's laboratory at UCSF almost
10 years ago. esiRNA has been a major research focus of my group ever since.
Sigma-Aldrich's extensive experience and product range in RNAi are a perfect
complement to our effort to produce efficient and specific esiRNAs."
Harvard Medical School, which has invested in a human genome-wide esiRNA library,
is using esiRNA to help identify the human genes that enable HIV propagation.
"The phenotypic results from the initial tests of MISSION esiRNA using
our assay for finding HIV dependency factors demonstrated very effective knockdown
over a wide range of genes," said Dr. Abraham Brass, a clinical research
fellow at Harvard Medical School.
Harvard Medical School will soon incorporate the technology into a wider range
of tests. Dr. Caroline Shamu, director of the ICCB-Longwood Screening Facility,
which provides high-throughput screens of RNAi libraries for Harvard Medical
School researchers, said, "We are looking forward to screening the MISSION
esiRNA library at ICCB-Longwood."
esiRNA are endoribonuclease-prepared siRNAs synthesized by in vitro transcription
of a 300-600-bp gene specific double-stranded RNA, followed by enzymatic digestion.
This collection of siRNA-like molecules is then purified, resulting in a complex
pool of siRNA molecules all targeting different sequences of a single gene.
For more information on MISSION(R) esiRNA, please visit www.sigma.com/esirna.